Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
  • April 24, 2025

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.

Merit Medical Systems (NASDAQ:MMSI) Surprises With Q1 Sales
  • April 24, 2025

Merit Medical Systems (NASDAQ:MMSI) Surprises With Q1 Sales

Medical device company Merit Medical Systems (NASDAQ:MMSI) announced better-than-expected revenue in Q1 CY2025, with sales up 9.8% year on year to $355.4 million. The company expects the full year’s revenue to be around $1.48 billion, close to analysts’ estimates. Its non-GAAP profit of $0.86 per share was 14.8% above analysts’ consensus estimates.

Why Sprinklr (CXM) Stock Is Up Today
  • April 24, 2025

Why Sprinklr (CXM) Stock Is Up Today

Shares of customer experience software provider Sprinklr (NYSE:CXM) jumped 5.4% in the afternoon session after stocks extended their rebound, led by strong gains in the technology sector, as renewed optimism surrounding U.S.–China trade negotiations lifted investor sentiment.